HealthDay - THURSDAY, Oct. 30 (HealthDay News) — In 2007, six major illnesses among Americans age 65 and older resulted in medical and lost productivity costs of more than $196 billion, according to researchers who analyzed Medicare and National Health Interview Survey data.
A new study in the Canadian Journal of Economics provides the first evidence on sexual orientation and economic outcomes in Canada. The study found that gay men have 12 percent lower personal incomes and lesbians have 15 percent higher personal incomes than heterosexual men and women. Christopher S.
More: continued here
Growing, the last book in Alzheimer’s Society’s Feelings Matter Most series, will be launched at the third national Dementia Congress in Bournemouth. The series challenges current practises and urges dementia care trainers to give dementia care the time it needs. Growing highlights the need to grow training from simple awareness raising to developing evidence-based learning.
More: continued here
According to an article published in the October 27 issue of Archives of Internal Medicine, poorer health outcomes were more likely among older white caregivers than black female caregivers who provide regular care or assistance for a child or who care for a disabled or sick adult. There are few studies, yielding inconsistent results, which suggest a relationship between caregiving and an increased likelihood of disease occurrence or death.
More: continued here
New hope has been offered to thousands of people in the early stages of Alzheimer’s today, 29 October, following a landmark decision in the House of Lords. The Lord’s denied the National Institute for Health and Clinical Excellence (NICE) the right to appeal a high court decision which, in May 2008, ordered NICE to release a copy of the model it used to restrict Alzheimer’s drugs on the NHS.
More: continued here
A promising drug for treatment ofcolorectal cancer may not be effective in 40 percent of patientswith the cancer, new research shows.
More: continued here
Abstract: Background: This work sought to determine the effects of hypothalamic proline-rich peptide (PRP)-1 in a rat model of Alzheimer’s disease.Methods: Complex histochemical, electrophysiologic, and behavioral analyses were performed on intact or diseased Wistar rats (n = 28). Pathologic conditions were induced by bilateral intracerebroventricular injection of amyloid peptide A?25–35. The diseased rats received systemic administration of PRP-1 or placebo control.Results: A?25–35 caused cellular neurodegeneration with marked glial reaction in the hippocampal complex and almost full destruction of the dentate fascia, which was not observed in conditions of PRP-1 administration after A?25–35 injection. Hippocampal neurons of intact animals responded to high-frequency (tetanic) stimulation of entorhinal cortex of ipsilateral cerebral hemisphere by tetanic and posttetanic potentiation of a different intensity and duration, which was accompanied by posttetanic depression. A?25–35 led to significant changes in the level and pattern of hippocampal neuronal activity, indicating the absence of both tetanic and posttetanic activity. Poststimulus activity manifestations rarely occurred and rapidly decreased after repeated trials. This indicated the focal character of lesion. Regular administration of PRP-1 for 4 weeks resulted in optimal restoration of electrophysiologic parameters. PRP-1 maintained the initial learning level achieved in a behavioral study in a Morris water maze.Conclusions: Systemic administration of PRP-1 possesses neuroprotective effects and can prevent the neurodegeneration in hippocampus induced by A?25–35. This suggests that PRP-1 could be a potential therapeutic agent for specific neurodegenerative diseases.
More: continued here
Researchers studying end-of-life preferences found that those most likely to change their end-of-life wishes are individuals who say they want aggressive care and individuals who do not have advance directives (such as living wills).
More: continued here
A common diabetes drug may help keeppatients from dying from one of the complications of thedisease.
More: continued here
Abstract: Background: This work sought to determine the effects of hypothalamic proline-rich peptide (PRP)-1 in a rat model of Alzheimer’s disease.Methods: Complex histochemical, electrophysiologic, and behavioral analyses were performed on intact or diseased Wistar rats (n = 28). Pathologic conditions were induced by bilateral intracerebroventricular injection of amyloid peptide A?25–35. The diseased rats received systemic administration of PRP-1 or placebo control.Results: A?25–35 caused cellular neurodegeneration with marked glial reaction in the hippocampal complex and almost full destruction of the dentate fascia, which was not observed in conditions of PRP-1 administration after A?25–35 injection. Hippocampal neurons of intact animals responded to high-frequency (tetanic) stimulation of entorhinal cortex of ipsilateral cerebral hemisphere by tetanic and posttetanic potentiation of a different intensity and duration, which was accompanied by posttetanic depression. A?25–35 led to significant changes in the level and pattern of hippocampal neuronal activity, indicating the absence of both tetanic and posttetanic activity. Poststimulus activity manifestations rarely occurred and rapidly decreased after repeated trials. This indicated the focal character of lesion. Regular administration of PRP-1 for 4 weeks resulted in optimal restoration of electrophysiologic parameters. PRP-1 maintained the initial learning level achieved in a behavioral study in a Morris water maze.Conclusions: Systemic administration of PRP-1 possesses neuroprotective effects and can prevent the neurodegeneration in hippocampus induced by A?25–35. This suggests that PRP-1 could be a potential therapeutic agent for specific neurodegenerative diseases.
More: continued here